CHRISTINEBEETONCHRISTINE BEETON0.000000000000000.000000000000001233BEETON, CHRISTINEImmunology, inflammation, autoimmunity, immunomodulation, immunomodulator, rheumatoid arthritis, multiple sclerosis, ion channel, lymphocyte, synoviocyte.Christine Beeton is an immunologist with an interest in autoimmunity and inflammation. She received a Bachelor and a Master of Science in Biochemistry from the Faculté des Sciences de Luminy within the Université de la Mediterranée in Marseille, France. She joined Dr. Evelyne Béraud’s group for her PhD in Immunology and then moved to the University of California, Irvine, to join Dr. K. George Chandy’s group in the Department of Physiology and Biophysics as a Postdoctoral Fellow in 2001. She was promoted to Assistant Researcher in 2006 and joined the faculty of the Department of Molecular Physiology and Biophysics at Baylor College of Medicine in 2008. In 2010 she assumed the role of Academic Director of the Cytometry and Cell Sorting Core for the Dan L. Duncan Cancer Center at Baylor College of Medicine.
As a Graduate Student, Christine Beeton was the first to show the benefits of blocking Kv1.1 and Kv1.3 channels with the scorpion venom peptide kaliotoxin to prevent and treat adoptive acute experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. She went on showing, in collaboration with Drs. Chandy and Wulff, that encephalitogenic T lymphocytes express more Kv1.3 channels than naïve T lymphocytes do and that targeting Kv1.3 channels only with ShK-Dap22 was sufficient to treat this model of multiple sclerosis. As a Postdoctoral Fellow, she continued her collaborative work with Dr. Wulff who showed that terminally differentiated human CCR7- effector memory T (TEM) lymphocytes up-regulate Kv1.3 channels upon activation whereas CCR7+ naïve and central memory T (TCM) lymphocytes up-regulate KCa3.1 channels. She demonstrated a similar switch in potassium channel phenotype in rat, but not mouse, T lymphocytes. In collaboration with the groups of Drs. Nepom, Andrews, and Calabresi she showed that T lymphocyte isolated from the synovial fluid of patients with rheumatoid arthritis and from the cerebrospinal fluid of patients with multiple sclerosis express high numbers of Kv1.3 channels. Through collaborative work with the groups of Drs. Pennington and Norton, she developed a novel analog of ShK, ShK-186 (now known as dalazatide), as a highly potent and selective blocker of Kv1.3 channels. ShK-186 preferentially inhibits human and rat TEM lymphocytes in vitro and in vivo and treats animal models of delayed type hypersensitivity, multiple sclerosis, rheumatoid arthritis, and asthma without preventing the clearance of acute viral or bacterial infections. Drs. Chandy, Beeton, and Pennington are inventors of a world-wide patent on ShK-186 and related compounds. This patent was licensed to Kineta, Inc. for the development of a new class of immunomodulators for the treatment of autoimmune diseases. Phase 1a and 1b clinical trials in healthy volunteers have shown that ShK-196 is well tolerated.
The Beeton Lab is interested in all aspects of translational research surrounding autoimmune and other chronic inflammatory diseases. Our expertise ranges from the isolation and culture of primary human and rodent cells (lymphocytes, monocyte/macrophages, and other immune cells; fibroblast-like synoviocytes; myoblasts), functional assays ex vivo (proliferation, production and secretion of cytokines, chemokines, proteases, migration, invasion, cytotoxicity, and more) and in vivo (trafficking, production and secretion of cytokines, chemokines, proteases, and more), patch-clamp electrophysiology on excitable and non-excitable cells for identification of ion channels and pharmacology of novel ion channel modulators, and animal models of inflammatory diseases in rats and mice (active and adoptive delayed type hypersensitivity, active and adoptive acute experimental autoimmune encephalomyelitis, chronic-relapsing experimental autoimmune encephalomyelitis, collagen-induced arthritis, pristane-induced arthritis, and adjuvant-induced arthritis). Our current work revolves around two main topics: targeting potassium channels for the treatment of chronic diseases (multiple sclerosis, rheumatoid arthritis, and type 1 myotonic dystrophy) and using antioxidant nanomaterials for the treatment of T lymphocyte-mediated autoimmune diseases (multiple sclerosis and rheumatoid arthritis).Professorplugins:FeaturedVideosFeatured Videosprns:awardConferredByaward conferred byprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provinceAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:awardOrHonorawards and honorsAward or Honor ReceiptDepartmentDivisionvivo:freetextKeywordkeywordsGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 802682Authorship 78958225603346Pennington MW, Chang SC, Chauhan S, Huq R, Tajhya RB, Chhabra S, Norton RS, Beeton CMarine drugsDevelopment of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs. 2015 Jan 16; 13(1):529-42.Mar Drugs2015-01-16T00:00:002015Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.Authorship 820284Authorship 851551Authorship 891481Authorship 9Authorship 157433Authorship 1574368Norton RS, Pennington MW, Beeton CTransforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases Venoms to drugs: Venom as a source for the development of human therapeutics, G.F. King, Editor. Transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. 2015.2015-02-11T00:00:002015Venoms to drugs: Venom as a source for the development of human therapeutics, G.F. King, EditorAuthorship 1583651625717360Lee CS, Dagnino-Acosta A, Yarotskyy V, Hanna A, Lyfenko A, Knoblauch M, Georgiou DK, Poch? RA, Swank MW, Long C, Ismailov II, Lanner J, Tran T, Dong K, Rodney GG, Dickinson ME, Beeton C, Zhang P, Dirksen RT, Hamilton SLSkeletal muscleCa(2+) permeation and/or binding to CaV1.1 fine-tunes skeletal muscle Ca(2+) signaling to sustain muscle function. Skelet Muscle. 2015; 5:4.Skelet Muscle2015-01-29T00:00:002015Ca(2+) permeation and/or binding to CaV1.1 fine-tunes skeletal muscle Ca(2+) signaling to sustain muscle function.Authorship 1194771Authorship 129Authorship 1587565Authorship 158757425869297Laragione T, Cheng KF, Tanner MR, He M, Beeton C, Al-Abed Y, Gulko PSClinical immunology (Orlando, Fla.)The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clin Immunol. 2015 Jun; 158(2):183-92.Clin Immunol2015-04-11T00:00:002015The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion.25864722Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RSThe FEBS journalN-Terminally extended analogues of the K? channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J. 2015 Jun; 282(12):2247-59.FEBS J2015-04-23T00:00:002015N-Terminally extended analogues of the K? channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.Authorship 33012Anesthesiology & PeriOperative MedicineGeneral Internal MedicineMD AndersonHUI-LINPANHUI-LIN PAN9317PAN, HUI-LINProfessorMARIA DE LOS ANGELESLOPEZ-OLIVOMARIA DE LOS ANGELES LOPEZ-OLIVO9353LOPEZ-OLIVO, MARIA DE LOS ANGELESAssistant ProfessorMARIASUAREZ-ALMAZORMARIA SUAREZ-ALMAZOR9347SUAREZ-ALMAZOR, MARIAProfessorAuthorship 451921Authorship 848554French Ministry of Women’s rights1991Prize for scientific vocationFrench Multiple Sclerosis Society (Association pour la Recherche sur la Sclérose en Plaques)20001998Pre-doctoral FellowshipFrench Medical Research Association (Fondation pour la Recherche Médicale)2001Dissertation FellowshipNational Multiple Sclerosis Society20042001Postdoctoral Fellowship American Heart Association2005Laverna Titus Award17th World Congress of the International Society on Toxinology2012Co-chair, session Toxins and Ion ChannelsOne Baylor PlazaHouston, 77030TX26508475Ayyar BV, Tajhya RB, Beeton C, Atassi MZScientific reportsAntigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep. 2015 Oct 28; 5:15776.Sci Rep2015-10-28T00:00:002015Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.Authorship 300327312634475Devaux J, Forni C, Beeton C, Barbaria J, B?raud E, Gola M, Crest MNeuroreportMyelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro. Neuroreport. 2003 Mar 03; 14(3):317-20.Neuroreport2003-03-03T00:00:002003Myelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro.Authorship 315669627165430Petho Z, Tanner MR, Tajhya RB, Huq R, Laragione T, Panyi G, Gulko PS, Beeton CArthritis research & therapyDifferent expression of ? subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes. Arthritis Res Ther. 2016 05 10; 18(1):103.Arthritis Res Ther2016-05-10T00:00:002016Different expression of ? subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes.74Professor10Assistant Professor54Instructor21Chair14Associate Professor78Professor Emeritus16043714Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PAProceedings of the National Academy of Sciences of the United States of AmericaThe voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11094-9.Proc Natl Acad Sci U S A2005-07-25T00:00:002005The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.14579513Wulff H, Beeton C, Chandy KGCurrent opinion in drug discovery & developmentPotassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7.Curr Opin Drug Discov Devel2003-09-01T00:00:002003Potassium channels as therapeutic targets for autoimmune disorders.12511563Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KGThe Journal of biological chemistryA novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003 Mar 14; 278(11):9928-37.J Biol Chem2003-01-02T00:00:002003A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.27654170Huq R, Samuel EL, Sikkema WK, Nilewski LG, Lee T, Tanner MR, Khan FS, Porter PC, Tajhya RB, Patel RS, Inoue T, Pautler RG, Corry DB, Tour JM, Beeton CScientific reportsPreferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. Sci Rep. 2016 Sep 22; 6:33808.Sci Rep2016-09-22T00:00:002016Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation.27552925Inoue T, Griffin DM, Huq R, Samuel EL, Ruano SH, Stinnett G, Majid TJ, Beeton C, Tour JM, Pautler RGNMR in biomedicineCharacterization of a novel MR-detectable nanoantioxidant that mitigates the recall immune response. NMR Biomed. 2016 10; 29(10):1436-44.NMR Biomed2016-08-24T00:00:002016Characterization of a novel MR-detectable nanoantioxidant that mitigates the recall immune response.Authorship 32708215Authorship 327442812782673Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KGThe Journal of clinical investigationThe voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun; 111(11):1703-13.J Clin Invest2003-06-01T00:00:002003The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.17984097Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RSThe Journal of biological chemistryThe D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. J Biol Chem. 2008 Jan 11; 283(2):988-97.J Biol Chem2007-11-05T00:00:002007The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.18979022Beeton C, Garcia A, Chandy KGJournal of visualized experiments : JoVEInduction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis. J Vis Exp. 2007; (5):224.J Vis Exp2007-07-04T00:00:002007Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis.15665253Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KGMolecular pharmacologyTargeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.Mol Pharmacol2005-01-21T00:00:002005Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.15155830Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, H?nsel W, Chandy KGMolecular pharmacologyKv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74.Mol Pharmacol2004-06-01T00:00:002004Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.16247791Carrega L, Mosbah A, Ferrat G, Beeton C, Andreotti N, Mansuelle P, Darbon H, De Waard M, Sabatier JMProteinsThe impact of the fourth disulfide bridge in scorpion toxins of the alpha-KTx6 subfamily. Proteins. 2005 Dec 01; 61(4):1010-23.Proteins2005-12-01T00:00:002005The impact of the fourth disulfide bridge in scorpion toxins of the alpha-KTx6 subfamily.21085107Hu X, Beeton CJournal of visualized experiments : JoVEDetection of functional matrix metalloproteinases by zymography. J Vis Exp. 2010 Nov 08; (45).J Vis Exp2010-11-08T00:00:002010Detection of functional matrix metalloproteinases by zymography.15498765Regaya I, Beeton C, Ferrat G, Andreotti N, Darbon H, De Waard M, Sabatier JMThe Journal of biological chemistryEvidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem. 2004 Dec 31; 279(53):55690-6.J Biol Chem2004-10-21T00:00:002004Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins.Authorship 328571327750479Fortune RD, Grill RJ, Beeton C, Tanner M, Huq R, Loose DSJournal of neurotraumaChanges in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury. J Neurotrauma. 2017 03 15; 34(6):1175-1186.J Neurotrauma2016-12-02T00:00:002016Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury.27763639Tajhya RB, Hu X, Tanner MR, Huq R, Kongchan N, Neilson JR, Rodney GG, Horrigan FT, Timchenko LT, Beeton CCell death & diseaseFunctional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis. 2016 10 20; 7(10):e2426.Cell Death Dis2016-10-20T00:00:002016Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts.21629267Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, Beeton C, Torossian S, Tatarian GG, Lee SU, Lau K, Walker E, Siminovitch KA, Chandy KG, Yu Z, Dennis JW, Demetriou MNature communicationsGenetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011; 2:334.Nat Commun2011-01-01T00:00:002011Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.Authorship 3749131021867724Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KGToxicon : official journal of the International Society on ToxinologyDevelopment of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012 Mar 15; 59(4):529-46.Toxicon2011-08-12T00:00:002011Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.22622363Varga Z, Gurrola-Briones G, Papp F, Rodr?guez de la Vega RC, Pedraza-Alva G, Tajhya RB, Gaspar R, Cardenas L, Rosenstein Y, Beeton C, Possani LD, Panyi GMolecular pharmacologyVm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.Mol Pharmacol2012-05-23T00:00:002012Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.22659540Chang SC, Galea CA, Leung EW, Tajhya RB, Beeton C, Pennington MW, Norton RSToxicon : official journal of the International Society on ToxinologyExpression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon. 2012 Oct; 60(5):840-50.Toxicon2012-05-31T00:00:002012Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.16282596Beeton C, Chandy KGThe Neuroscientist : a review journal bringing neurobiology, neurology and psychiatryPotassium channels, memory T cells, and multiple sclerosis. Neuroscientist. 2005 Dec; 11(6):550-62.Neuroscientist2005-12-01T00:00:002005Potassium channels, memory T cells, and multiple sclerosis.23063513Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RSFEBS lettersA C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.FEBS Lett2012-10-09T00:00:002012A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.18041678Beeton CIDrugs : the investigational drugs journalDiscovery on Target 2007--CHI's Fifth Annual Conference. Ion channels. IDrugs. 2007 Dec; 10(12):851-4.IDrugs2007-12-01T00:00:002007Discovery on Target 2007--CHI's Fifth Annual Conference. Ion channels.Authorship 100075118835197Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Fl?gel A, Pennington MW, Parker I, Chandy KG, Cahalan MDImmunityImaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14.Immunity2008-10-02T00:00:002008Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.18989399Beeton C, Chandy KGJournal of visualized experiments : JoVEPreparing T cell growth factor from rat splenocytes. J Vis Exp. 2007; (10):402.J Vis Exp2007-10-31T00:00:002007Preparing T cell growth factor from rat splenocytes.18989401Beeton C, Chandy KGJournal of visualized experiments : JoVEIsolation of mononuclear cells from the central nervous system of rats with EAE. J Vis Exp. 2007; (10):527.J Vis Exp2007-12-04T00:00:002007Isolation of mononuclear cells from the central nervous system of rats with EAE.18989426Beeton C, Chandy KGJournal of visualized experiments : JoVEEnrichment of NK cells from human blood with the RosetteSep kit from StemCell technologies. J Vis Exp. 2007; (8):326.J Vis Exp2007-10-01T00:00:002007Enrichment of NK cells from human blood with the RosetteSep kit from StemCell technologies.18989437Beeton C, Garcia A, Chandy KGJournal of visualized experiments : JoVEDrawing blood from rats through the saphenous vein and by cardiac puncture. J Vis Exp. 2007; (7):266.J Vis Exp2007-08-23T00:00:002007Drawing blood from rats through the saphenous vein and by cardiac puncture.18997885Beeton C, Chandy KGJournal of visualized experiments : JoVEInduction and monitoring of active delayed type hypersensitivity (DTH) in rats. J Vis Exp. 2007; (6):237.J Vis Exp2007-07-19T00:00:002007Induction and monitoring of active delayed type hypersensitivity (DTH) in rats.19066497Matheu MP, Beeton C, Parker I, Chandy KG, D Cahalan MJournal of visualized experiments : JoVEImaging effector memory T cells in the ear after induction of adoptive DTH. J Vis Exp. 2008 Aug 14; (18).J Vis Exp2008-08-14T00:00:002008Imaging effector memory T cells in the ear after induction of adoptive DTH.19122005Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KGMolecular pharmacologyEngineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr; 75(4):762-73.Mol Pharmacol2009-01-02T00:00:002009Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.19252470Beeton C, Chandy KGJournal of visualized experiments : JoVEInduction and monitoring of adoptive delayed-type hypersensitivity in rats. J Vis Exp. 2007 Oct 01; (8).J Vis Exp2007-10-01T00:00:002007Induction and monitoring of adoptive delayed-type hypersensitivity in rats.Chandy KG, Beeton C, Pennington MWAnalogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channelsAnalogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels. 2006.2006-01-01T00:00:002006Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channelsWulff H, Beeton C, Calabresi PA, Gutman GA, Pennington MW, Chandy KG The Kv1.3 potassium channel: physiology, pharmacology and therapeutic indicationsVoltage-gated ion channels as drug targets, D.J. Triggle, M. Gopalakrishnan, D. Rampe, Editors. The Kv1.3 potassium channel: physiology, pharmacology and therapeutic indications. 2006; ISBN 3-527-31258-7.2006-01-01T00:00:002006Voltage-gated ion channels as drug targets, D.J. Triggle, M. Gopalakrishnan, D. Rampe, Editors21085106Koshy S, Alizadeh P, Timchenko LT, Beeton CJournal of visualized experiments : JoVEQuantitative measurement of GLUT4 translocation to the plasma membrane by flow cytometry. J Vis Exp. 2010 Nov 07; (45).J Vis Exp2010-11-07T00:00:002010Quantitative measurement of GLUT4 translocation to the plasma membrane by flow cytometry.MARCODE GIORGIMARCO DE GIORGI12815DE GIORGI, MARCOInstructor21824083Beeton C, Pennington MW, Norton RSInflammation & allergy drug targetsAnalogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.Inflamm Allergy Drug Targets2011-10-01T00:00:002011Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.23300835Anangi R, Koshy S, Huq R, Beeton C, Chuang WJ, King GFPloS oneRecombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers. PLoS One. 2012; 7(12):e52965.PLoS One2012-12-26T00:00:002012Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers.22074915Hu X, Laragione T, Sun L, Koshy S, Jones KR, Ismailov II, Yotnda P, Horrigan FT, Gulko PS, Beeton CThe Journal of biological chemistryKCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis. J Biol Chem. 2012 Feb 03; 287(6):4014-22.J Biol Chem2011-11-10T00:00:002011KCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis.22637724Tarcha EJ, Chi V, Mu?oz-El?as EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SPThe Journal of pharmacology and experimental therapeuticsDurable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53.J Pharmacol Exp Ther2012-05-25T00:00:002012Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.Beeton CPotassium channel blockers: immunosuppressive properties and therapy of experimental autoimmune encephalomyelitisPotassium channel blockers: immunosuppressive properties and therapy of experimental autoimmune encephalomyelitis. 2001.2001-01-01T00:00:002001Potassium channel blockers: immunosuppressive properties and therapy of experimental autoimmune encephalomyelitisAuthorship 868349328299740Tajhya RB, Patel RS, Beeton CMethods in molecular biology (Clifton, N.J.)Detection of Matrix Metalloproteinases by Zymography. Methods Mol Biol. 2017; 1579:231-244.Methods Mol Biol2017-01-01T00:00:002017Detection of Matrix Metalloproteinases by Zymography.28389388Tanner MR, Tajhya RB, Huq R, Gehrmann EJ, Rodarte KE, Atik MA, Norton RS, Pennington MW, Beeton CClinical immunology (Orlando, Fla.)Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.Clin Immunol2017-04-04T00:00:002017Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.Authorship 868968928428266Tanner MR, Pennington MW, Laragione T, Gulko PS, Beeton CFASEB journal : official publication of the Federation of American Societies for Experimental BiologyKCa1.1 channels regulate ?1-integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes. FASEB J. 2017 08; 31(8):3309-3320.FASEB J2017-04-20T00:00:002017KCa1.1 channels regulate ?1-integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes.Authorship 8692924Authorship 1023881Authorship 872854628623364Bergmann R, Kubeil M, Zarschler K, Chhabra S, Tajhya RB, Beeton C, Pennington MW, Bachmann M, Norton RS, Stephan HScientific reportsDistribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep. 2017 06 16; 7(1):3756.Sci Rep2017-06-16T00:00:002017Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.Beeton C, Gutman GA, Chandy KGTargets and therapeutic properties of venom peptides The handbook of peptides, A.J. Kastin, Editor. Targets and therapeutic properties of venom peptides. 2006; ISBN 0123694426 .2006-01-01T00:00:002006The handbook of peptides, A.J. Kastin, Editor15120495Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MDTrends in pharmacological sciencesK+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004 May; 25(5):280-9.Trends Pharmacol Sci2004-05-01T00:00:002004K+ channels as targets for specific immunomodulation.17088564Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KGProceedings of the National Academy of Sciences of the United States of AmericaKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9.Proc Natl Acad Sci U S A2006-11-06T00:00:002006Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.Authorship 8777291Authorship 877730229076378Beeton CExpert opinion on therapeutic targetsKCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opin Ther Targets. 2017 12; 21(12):1077-1081.Expert Opin Ther Targets2017-10-31T00:00:002017KCa1.1 channels as therapeutic targets for rheumatoid arthritis.28930537Tanner MR, Beeton CFrontiers in bioscience (Landmark edition)Differences in ion channel phenotype and function between humans and animal models. Front Biosci (Landmark Ed). 2018 01 01; 23(1):43-64.Front Biosci (Landmark Ed)2018-01-01T00:00:002018Differences in ion channel phenotype and function between humans and animal models.Béraud E, Devaux J, Beeton C, Clot-Faybesse O, Barbaria J, Crest MPotassium channel blockers modify central nervous conduction, inhibit T-lymphocyte proliferation, and improve experimental autoimmune encephalomyelitisIon channels and physiopathologies of nerve conduction and cell proliferation, B. Rouzaire-Dubois, E. Benoit & J.M. Dubois, Editors. Potassium channel blockers modify central nervous conduction, inhibit T-lymphocyte proliferation, and improve experimental autoimmune encephalomyelitis. 2002; ISBN 81-7736-135-X.2002-01-01T00:00:002002Ion channels and physiopathologies of nerve conduction and cell proliferation, B. Rouzaire-Dubois, E. Benoit & J.M. Dubois, EditorsAuthorship 881442729453198Tanner MR, Pennington MW, Chamberlain BH, Huq R, Gehrmann EJ, Laragione T, Gulko PS, Beeton CThe Journal of pharmacology and experimental therapeuticsTargeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis. J Pharmacol Exp Ther. 2018 05; 365(2):227-236.J Pharmacol Exp Ther2018-02-16T00:00:002018Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis.true1InstructorInstructorD001327Disorders2524020.752664Autoimmune DiseasesD051037Chemicals & Drugs9270.97654Large-Conductance Calcium-Activated Potassium Channel alpha SubunitsD001172Disorders1234080.721182Arthritis, RheumatoidD026902Chemicals & Drugs451100.947989Potassium Channel BlockersD051664Chemicals & Drugs6360.973979Kv1.3 Potassium ChannelAuthorship 92987017Authorship 935948529802206Yao C, Veleva T, Scott L, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, M?ller FU, El-Armouche A, Tony Eissa N, Beeton C, Nattel S, Wehrens XHT, Dobrev D, Li NCirculationEnhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 11 13; 138(20):2227-2242.Circulation2018-11-13T00:00:002018Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.30612588Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton CArthritis research & therapyKCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 01 07; 21(1):6.Arthritis Res Ther2019-01-07T00:00:002019KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.2019-03-12NIHBEETON, CHRISTINE2018-03-13Union Biometrica BioSorterS10OD0252512013-06-30NIHBEETON, CHRISTINE2010-07-01Potassium channels in myotonic dystrophy type 1R03AR0598382012-01-31NIHBEETON, CHRISTINE2010-08-18Targeting T lymphocyte potassium channels for the treatment of asthma--OLDR56AI0849812021-06-30NIHBEETON, CHRISTINE2018-12-01In vivo production of a potassium channel inhibitor for immunomodulationR21AI1368762017-05-31NIHBEETON, CHRISTINE2011-09-01New Peptides for the Treatment of Multiple SclerosisR01NS073712Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 12262610Department of Medicine24146918Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton CPloS oneBlocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740.PLoS One2013-10-11T00:00:002013Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes.Medicine-Immunology, Allergy, RheumMedicine-PulmonaryMolecular Physiology & BiophysicsBaylor College of Medicine4.580040.00645869368research areas0.4241030.031640926coauthor of50.71837.6391360similar to1182selected publicationsFRANKHORRIGANFRANK HORRIGAN0.000000000000000.000000000000001467HORRIGAN, FRANKAssociate ProfessorMATASSIM ATASSI0.000000000000000.000000000000003024ATASSI, MProfessor EmeritusSTEENPEDERSENSTEEN PEDERSEN0.000000000000000.000000000000003303PEDERSEN, STEENAssistant ProfessorROBIAPAUTLERROBIA PAUTLER0.000000000000000.00000000000000561PAUTLER, ROBIAProfessorMUSTAFAATIKMUSTAFA ATIK29.70990600000000-95.40283000000000807ATIK, MUSTAFAInstructorDAVIDCORRYDAVID CORRY0.000000000000000.0000000000000064CORRY, DAVIDProfessorSUSANHAMILTONSUSAN HAMILTON0.000000000000000.0000000000000028HAMILTON, SUSANProfessorWILLIAMLAGORWILLIAM LAGOR0.000000000000000.000000000000004763LAGOR, WILLIAMProfessorAuthorship 11098119Baylor College of Medicine2018Clark Faculty Service AwardPrincipal Investigator2023-08-30Cancer prevention and Research Institute of Texas (CPRIT)Beeton, Christine2018-08-31Advanced multiparametric cytometry and cell sorting coreRP1806721Authorship 1110302Authorship 1079713Authorship 9564632831585809Johnson JL, Stoica L, Liu Y, Zhu PJ, Bhattacharya A, Buffington SA, Huq R, Eissa NT, Larsson O, Porse BT, Domingo D, Nawaz U, Carroll R, Jolly L, Scerri TS, Kim HG, Brignell A, Coleman MJ, Braden R, Kini U, Jackson V, Baxter A, Bahlo M, Scheffer IE, Amor DJ, Hildebrand MS, Bonnen PE, Beeton C, Gecz J, Morgan AT, Costa-Mattioli MNeuronInhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response. Neuron. 2019 11 20; 104(4):665-679.e8.Neuron2019-10-01T00:00:002019Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response.true1ProfessorProfessorIVANROSASIVAN ROSAS15330ROSAS, IVANProfessorAuthorship 110Authorship 9883301032348718Li A, Tanner MR, Lee CM, Hurley AE, De Giorgi M, Jarrett KE, Davis TH, Doerfler AM, Bao G, Beeton C, Lagor WRMolecular therapy : the journal of the American Society of Gene TherapyAAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Mol Ther. 2020 Jun 03; 28(6):1432-1441.Mol Ther2020-04-19T00:00:002020AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.Authorship 9978723232832873Ong ST, Bajaj S, Tanner MR, Chang SC, Krishnarjuna B, Ng XR, Morales RAV, Chen MW, Luo D, Patel D, Yasmin S, Ng JJH, Zhuang Z, Nguyen HM, El Sahili A, Lescar J, Patil R, Charman SA, Robins EG, Goggi JL, Tan PW, Sadasivam P, Ramasamy B, Hartimath SV, Dhawan V, Bednenko J, Colussi P, Wulff H, Pennington MW, Kuyucak S, Norton RS, Beeton C, Chandy KGACS pharmacology & translational scienceModulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. ACS Pharmacol Transl Sci. 2020 Aug 14; 3(4):720-736.ACS Pharmacol Transl Sci2020-05-14T00:00:002020Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin.Authorship 10031991133081234Tanner MR, Huq R, Sikkema WKA, Nilewski LG, Yosef N, Schmitt C, Flores-Suarez CP, Raugh A, Laragione T, Gulko PS, Tour JM, Beeton CAntioxidants (Basel, Switzerland)Antioxidant Carbon Nanoparticles Inhibit Fibroblast-Like Synoviocyte Invasiveness and Reduce Disease Severity in a Rat Model of Rheumatoid Arthritis. Antioxidants (Basel). 2020 Oct 16; 9(10).Antioxidants (Basel)2020-10-16T00:00:002020Antioxidant Carbon Nanoparticles Inhibit Fibroblast-Like Synoviocyte Invasiveness and Reduce Disease Severity in a Rat Model of Rheumatoid Arthritis.Authorship 116822true1ProfessorProfessorAuthorship 1031352334630091Markakis I, Charitakis I, Beeton C, Galani M, Repousi E, Aggeloglou S, Sfikakis PP, Pennington MW, Chandy KG, Poulopoulou CFrontiers in pharmacologyKv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis. Front Pharmacol. 2021; 12:714841.Front Pharmacol2021-09-23T00:00:002021Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis.Authorship 10377461135181688Tsoyi K, Esposito AJ, Sun B, Bowen RG, Xiong K, Poli F, Cardenas R, Chu SG, Liang X, Ryter SW, Beeton C, Doyle TJ, Robertson MJ, Celada LJ, Romero F, El-Chemaly SY, Perrella MA, Ho IC, Rosas IOScientific reportsSyndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Sci Rep. 2022 02 18; 12(1):2847.Sci Rep2022-02-18T00:00:002022Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts.Authorship 137478824244345Rashid MH, Heinzelmann G, Huq R, Tajhya RB, Chang SC, Chhabra S, Pennington MW, Beeton C, Norton RS, Kuyucak SPloS oneA potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One. 2013; 8(11):e78712.PLoS One2013-11-07T00:00:002013A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.true1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate ProfessorDepartment of Integrative Physiologytrue1InstructorInstructortrue1ProfessorProfessorAuthorship 1062554836595694Wang Y, Zhu D, Ortiz-Velez LC, Perry JL, Pennington MW, Hyser JM, Britton RA, Beeton CProceedings of the National Academy of Sciences of the United States of AmericaA bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.Proc Natl Acad Sci U S A2023-01-03T00:00:002023A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.Authorship 181293Authorship 1067944837040361Wang Y, Hurley A, De Giorgi M, Tanner MR, Hu RC, Pennington MW, Lagor WR, Beeton CPloS oneAdeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver. PLoS One. 2023; 18(4):e0283996.PLoS One2023-04-11T00:00:002023Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver.Authorship 1069417437201335Laragione T, Harris C, Azizgolshani N, Beeton C, Bongers G, Gulko PSEBioMedicineMagnesium increases numbers of Foxp3+ Treg cells and reduces arthritis severity and joint damage in an IL-10-dependent manner mediated by the intestinal microbiome. EBioMedicine. 2023 Jun; 92:104603.EBioMedicine2023-05-16T00:00:002023Magnesium increases numbers of Foxp3+ Treg cells and reduces arthritis severity and joint damage in an IL-10-dependent manner mediated by the intestinal microbiome.true1ProfessorProfessortrue1Professor EmeritusProfessor EmeritusDepartment of Biochemistry and Molecular PharmacologyBiochemistry & Mol PharmacologyAuthorship 205Authorship 163Authorship 224851true1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessorAuthorship 216834Authorship 1385191Authorship 1385208Authorship 1385219Authorship 13852215269656Devaux J, Beeton C, B?raud E, Crest MRevue neurologique[Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers]. Rev Neurol (Paris). 2004 May; 160(5 Pt 2):S16-27.Rev Neurol (Paris)2004-05-01T00:00:002004[Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers].11717451Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, B?raud EProceedings of the National Academy of Sciences of the United States of AmericaSelective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13942-7.Proc Natl Acad Sci U S A2001-11-20T00:00:002001Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.11145670Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, B?raud EJournal of immunology (Baltimore, Md. : 1950)Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.J Immunol2001-01-15T00:00:002001Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.Beeton C.Targets and therapeutic properties of venom peptides The handbook of peptides, 2nd edition, A.J. Kastin, Editor. Targets and therapeutic properties of venom peptides. 2013; ISBN 978-0-12-385095-9.2013-01-01T00:00:002013The handbook of peptides, 2nd edition, A.J. Kastin, EditorAuthorship 1390241024644290Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton CThe Journal of biological chemistryBlocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.J Biol Chem2014-03-18T00:00:002014Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.Authorship 230821Authorship 23338124676092Rashid MH, Huq R, Tanner MR, Chhabra S, Khoo KK, Estrada R, Dhawan V, Chauhan S, Pennington MW, Beeton C, Kuyucak S, Norton RSScientific reportsA potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.Sci Rep2014-03-28T00:00:002014A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.Authorship 335641Authorship 255599Authorship 13959910Authorship 299121Authorship 142810224493754Panyi G, Beeton C, Felipe APhilosophical transactions of the Royal Society of London. Series B, Biological sciencesIon channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci. 2014 Mar 19; 369(1638):20130106.Philos Trans R Soc Lond B Biol Sci2014-02-03T00:00:002014Ion channels and anti-cancer immunity.24891519Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KGFASEB journal : official publication of the Federation of American Societies for Experimental BiologyKv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64.FASEB J2014-06-02T00:00:002014Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.Authorship 14393119Authorship 391183Authorship 416807Authorship 144156424936214Hoa NT, Ge L, Tajhya RB, Beeton C, Cornforth AN, Abolhoda A, Lambrecht N, DaCosta-Iyer M, Ouyang Y, Mai AP, Hong E, Shon J, Hickey MJ, Erickson KL, Kruse CA, Jadus MRAmerican journal of translational researchSmall cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease. Am J Transl Res. 2014; 6(3):188-205.Am J Transl Res2014-05-15T00:00:002014Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.Authorship 147296725027630Ge L, Hoa NT, Wilson Z, Arismendi-Morillo G, Kong XT, Tajhya RB, Beeton C, Jadus MRInternational immunopharmacologyBig Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. Int Immunopharmacol. 2014 Oct; 22(2):427-43.Int Immunopharmacol2014-07-12T00:00:002014Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.Authorship 6941911Authorship 512871Authorship 727281Authorship 746871Authorship 534351Authorship 149501925252152Tanner MR, Hu X, Huq R, Tajhya RB, Sun L, Khan FS, Laragione T, Horrigan FT, Gulko PS, Beeton CArthritis & rheumatology (Hoboken, N.J.)KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis. Arthritis Rheumatol. 2015 Jan; 67(1):96-106.Arthritis Rheumatol2015-01-01T00:00:002015KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis.Authorship 604236Authorship 639855Authorship 66629Authorship 981052Authorship 790492